Amundi Neurocrine Biosciences Inc Transaction History

Amundi

$295 Billion
Q3 2025

A detailed history of Amundi transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Amundi holds 230,263 shares of NBIX stock, worth $33.4 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

230,263

Previous 219,195 5.05%

Holding current value

$33.4 Million

Previous $27.6 Million 17.33%

% of portfolio

0.01%

Previous 0.01%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$123.98 - $146.67 $1.37 Million - $1.62 Million	11,068 Added 5.05%	230,263 $32.3 Million
Q2 2025 Aug 13, 2025	SELL	$87.54 - $128.18 $1.05 Million - $1.54 Million	-11,992 Reduced 5.19%	219,195 $27.6 Million
Q1 2025 May 15, 2025	SELL	$107.22 - $153.29 $3.29 Million - $4.7 Million	-30,673 Reduced 11.71%	231,187 $25.6 Million
Q4 2024 Feb 07, 2025	SELL	$111.62 - $139.44 $44.1 Million - $55.1 Million	-394,835 Reduced 60.12%	261,860 $35.7 Million
Q3 2024 Nov 13, 2024	BUY	$114.58 - $153.15 $30.4 Million - $40.6 Million	265,382 Added 67.82%	656,695 $75.6 Million

Q2 2024 Aug 14, 2024	BUY	$130.86 - $143.19 $3.88 Million - $4.24 Million	29,641 Added 8.2%	391,313 $53.9 Million
Q1 2024 May 15, 2024	BUY	$130.4 - $143.74 $2.8 Million - $3.08 Million	21,458 Added 6.31%	361,672 $49.9 Million
Q4 2023 Feb 14, 2024	BUY	$106.07 - $132.76 $3.69 Million - $4.62 Million	34,820 Added 11.4%	340,214 $44.8 Million
Q3 2023 Nov 14, 2023	SELL	$94.02 - $117.1 $83.2 Million - $104 Million	-884,632 Reduced 74.34%	305,394 $34.4 Million
Q2 2023 Aug 14, 2023	SELL	$89.53 - $104.87 $2.85 Million - $3.34 Million	-31,815 Reduced 2.6%	1,190,026 $112 Million
Q1 2023 May 15, 2023	BUY	$94.11 - $123.02 $28.1 Million - $36.7 Million	298,475 Added 32.32%	1,221,841 $124 Million
Q4 2022 Feb 14, 2023	BUY	$106.72 - $127.06 $11.4 Million - $13.5 Million	106,554 Added 13.05%	923,366 $110 Million
Q3 2022 Nov 14, 2022	BUY	$92.03 - $107.81 $69.2 Million - $81 Million	751,542 Added 1151.44%	816,812 $88.7 Million
Q2 2022 Aug 15, 2022	SELL	$75.79 - $100.07 $44,033 - $58,140	-581 Reduced 0.88%	65,270 $6.15 Million
Q1 2022 May 16, 2022	SELL	$72.45 - $94.81 $5.33 Million - $6.98 Million	-73,571 Reduced 52.77%	65,851 $6.49 Million
Q4 2021 Feb 14, 2022	BUY	$79.65 - $106.22 $121,625 - $162,197	1,527 Added 1.11%	139,422 $11 Million
Q3 2021 Nov 15, 2021	BUY	$86.18 - $99.03 $1.39 Million - $1.6 Million	16,109 Added 13.23%	137,895 $13.2 Million
Q2 2021 Aug 16, 2021	BUY	$89.43 - $102.27 $10.9 Million - $12.5 Million	121,786 New	121,786 $11.9 Million

Others Institutions Holding NBIX

# of Institutions

726

Shares Held

102M

Call Options Held

230K

Put Options Held

477K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13.9B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Amundi, based on Form 13F filings with the SEC.

News

Stay updated on Amundi with notifications on news.

Account